Press Releases

March 15, 2018
— Phase 3 PFIC trial of IBAT inhibitor A4250 planned to initiate in spring 2018 — — Elobixibat approved in Japan , becoming the first IBAT inhibitor approved in the world — — ~$200 million current cash balance expected to be sufficient to fund operations into 2021 — — Management to host conference
January 25, 2018
BOSTON , Jan. 25, 2018 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq:ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, announced today the pricing of its previously announced underwritten public offering of 1,970,000 shares of its common stock
January 24, 2018
BOSTON , Jan. 24, 2018 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq:ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, announced today that it has commenced an underwritten public offering of its common stock.
January 19, 2018
— Elobixibat approved in Japan for the treatment of chronic constipation — — Albireo innovation leads to world’s first approved ileal bile acid transporter (IBAT) inhibitor — BOSTON , Jan. 19, 2018 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq:ALBO), a clinical-stage orphan pediatric liver
January 3, 2018
BOSTON, Jan. 03, 2018 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (NASDAQ:ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that subsidiary Elobix AB has entered into an agreement with HealthCare Royalty Partners (HCR) to monetize its royalty rights under its license agreement with EA Pharma Co., Ltd.